A Pilot Study of Long‐Term Weekly Interferon‐β Administration for Chronic Hepatitis B

Tatehiro Kagawa, Toshio Morizane, Hidetsugu Saito, Satoshi Tsunematsu, Shinichirou Tada, Naoki Kumagai, Kanji Tsuchimoto, Hitoshi Sugiura, Makio Mukai, Masaharu Tsuchiya

Research output: Contribution to journalArticle

22 Citations (Scopus)


Interferon‐β was given weekly for 24 wk, at a dose of 3 million units, intravenously, to 10 patients with chronic hepatitis B who were serologically positive for HBsAg and HBeAg. Their condition was followed for 6 months after the end of therapy. Both serum hepatitis B virus‐associated DNA‐polymerase activity and alanine aminotransferase level became significantly lower during therapy and during the 6 months after the end of therapy than at the beginning of therapy. In five of 10 patients, the seroconversion from HBeAg positive to anti‐HBe positive had occurred by 6 months after the end of therapy, and in four of these five patients, serum alanine aminotransferase level became normal. Weekly interferon‐β administration over 6 months seems effective in inducing seroconversion and in normalizing serum alanine aminotransferase level.

Original languageEnglish
Pages (from-to)212-216
Number of pages5
JournalThe American Journal of Gastroenterology
Issue number2
Publication statusPublished - 1993 Feb


ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Kagawa, T., Morizane, T., Saito, H., Tsunematsu, S., Tada, S., Kumagai, N., Tsuchimoto, K., Sugiura, H., Mukai, M., & Tsuchiya, M. (1993). A Pilot Study of Long‐Term Weekly Interferon‐β Administration for Chronic Hepatitis B. The American Journal of Gastroenterology, 88(2), 212-216. https://doi.org/10.1111/j.1572-0241.1993.tb07507.x